Compare stocks

Bavarian Nordic A/S is a biotechnology company based in Denmark, primarily focused on the development, manufacture, and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company's product portfolio includes vaccines for smallpox, Ebola, and other infectious diseases, with its most notable products being the smallpox and monkeypox vaccine, Jynneos (also known as Imvanex or Imvamune). Founded in 1994, Bavarian Nordic has established partnerships with several government agencies, enhancing its strategic positioning in the vaccine development sector. The company operates globally, with its headquarters located in Kvistgaard, Denmark, and manufacturing facilities in various locations supporting its international distribution efforts. Bavarian Nordic leverages proprietary vaccine platform technologies such as MVA-BN, contributing to its competitive advantage in the biotechnology industry.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.